200,000+ products from a single source!

sales@angenechem.com

Home > Indoles and Oxindole > 187947-37-1

187947-37-1

187947-37-1 | 5,8,11,14-Eicosatetraenamide, N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-, (5Z,8Z,11Z,14Z)-

CAS No: 187947-37-1 Catalog No: AG002GLA MDL No:MFCD02179189

Product Description

Catalog Number:
AG002GLA
Chemical Name:
5,8,11,14-Eicosatetraenamide, N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-, (5Z,8Z,11Z,14Z)-
CAS Number:
187947-37-1
Molecular Formula:
C30H42N2O2
Molecular Weight:
462.6667
MDL Number:
MFCD02179189
IUPAC Name:
(5Z,8Z,11Z,14Z)-N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]icosa-5,8,11,14-tetraenamide
InChI:
InChI=1S/C30H42N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-30(34)31-23-22-26-25-32-29-21-20-27(33)24-28(26)29/h6-7,9-10,12-13,15-16,20-21,24-25,32-33H,2-5,8,11,14,17-19,22-23H2,1H3,(H,31,34)/b7-6-,10-9-,13-12-,16-15-
InChI Key:
QJDNHGXNNRLIGA-DOFZRALJSA-N
SMILES:
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCCc1c[nH]c2c1cc(O)cc2

Properties

Complexity:
652  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
4  
Exact Mass:
462.325g/mol
Formal Charge:
0
Heavy Atom Count:
34  
Hydrogen Bond Acceptor Count:
2  
Hydrogen Bond Donor Count:
3  
Isotope Atom Count:
0
Molecular Weight:
462.678g/mol
Monoisotopic Mass:
462.325g/mol
Rotatable Bond Count:
17  
Topological Polar Surface Area:
65.1A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
7  

Literature

Title Journal
Oxidation of endogenous N-arachidonoylserotonin by human cytochrome P450 2U1. The Journal of biological chemistry 20140411
N-arachidonoyl-serotonin in the basolateral amygdala increases anxiolytic behavior in the elevated plus maze. Behavioural brain research 20120801
The blockade of the transient receptor potential vanilloid type 1 and fatty acid amide hydrolase decreases symptoms and central sequelae in the medial prefrontal cortex of neuropathic rats. Molecular pain 20110101
The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. Pharmacological research 20100601
Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacological research 20100401
Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands. Bioorganic & medicinal chemistry letters 20091201
Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems. Neurobiology of disease 20091001
Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090201
The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. Neuropharmacology 20081201
Inhibiting parabrachial fatty acid amide hydrolase activity selectively increases the intake of palatable food via cannabinoid CB1 receptors. American journal of physiology. Regulatory, integrative and comparative physiology 20081101
Neuronal and glial alterations in the cerebellar cortex of maternally deprived rats: gender differences and modulatory effects of two inhibitors of endocannabinoid inactivation. Developmental neurobiology 20081001
Gender-dependent cellular and biochemical effects of maternal deprivation on the hippocampus of neonatal rats: a possible role for the endocannabinoid system. Developmental neurobiology 20080915
New N-arachidonoylserotonin analogues with potential 'dual' mechanism of action against pain. Journal of medicinal chemistry 20071227
Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. Journal of molecular medicine (Berlin, Germany) 20071201
Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. British journal of pharmacology 20070801
Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. British journal of pharmacology 20070301
Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biological psychiatry 20060315
Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology 20060301
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20060301
Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology 20050901
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. Journal of medicinal chemistry 20050811
Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochemical pharmacology 20050801
A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20041001
Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin. Journal of enzyme inhibition and medicinal chemistry 20030601

© 2019 Angene International Limited. All rights Reserved.